AURKA and thyroid cancer: A previous study showed that one AURKA inhibitor, MLN8237, had antitumor effects in thyroid cancer with high c-Myc expression but not in thyroid cancer with low c-Myc expression, suggesting that targeting AURKA may be an effective therapeutic strategy for c-Myc-overexpressing thyroid cancers [18].